Currently, there are 10.10M common shares owned by the public and among those 9.17M shares have been available to trade.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 357,526 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 0.4900, up 0.91%. The company’s stock has a 5-day price change of -57.04% and -55.39% over the past three months. DMK shares are trading -66.87% year to date (YTD), with the 12-month market performance down to -98.49% lower. It has a 12-month low price of $0.21 and touched a high of $21.70 over the same period. DMK has an average intraday trading volume of 716.60K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -59.94%, -61.75%, and -85.17% respectively.
Institutional ownership of DMK Pharmaceuticals Corp (NASDAQ: DMK) shares accounts for 2.44% of the company’s 10.10M shares outstanding.
It has a market capitalization of $2.34M and a beta (3y monthly) value of 1.09. The earnings-per-share (ttm) stands at -$9.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 59.07% over the week and 20.41% over the month.
Analysts forecast that DMK Pharmaceuticals Corp (DMK) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$4.39 for 2023. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.08 a year ago.
Looking at the support for the DMK, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on May 13, 2020, with the firm’s price target at $1.50.
